AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24667140 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% hypoxic VO(2)peak performed in a normoxic environment (HI-NE)
Number of subjects: 11
Study 24667140 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% hypoxic VO(2)peak performed in a hypoxic environment (HI-HE)
Number of subjects: 11
Study 24667140 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 11
Study 23015193 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA (alteplase)
Number of subjects: 800
Study 23015193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 21123471 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional swaddling
Number of subjects: 1279
Study 21123471 — intervention group
Group type: COMPARATOR
Intervention: Nonswaddling
Number of subjects: 1279
Study 17651058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence (above median diet score)
Number of subjects: 3042
Study 17651058 — intervention group
Group type: COMPARATOR
Intervention: Unhealthy diet adherence (below median diet score)
Number of subjects: 3042
Study 15951518 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback
Number of subjects: 0
Study 11113795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberotomy performed on 11 patients 1 week before debonding
Number of subjects: 23
Study 11113795 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 patients)
Number of subjects: 23
Study 9028551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CMV hyperimmune globulin (0.4 g/kg on day -8, 0.2 g/kg on days -1, +7, +14, +21, +28, +35, +42, +56, +70)
Number of subjects: 28
Study 9028551 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 28
Study 9028551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 28
Study 8301064 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 114
Study 8301064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 3492974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2 mg/kg)
Number of subjects: 91
Study 3492974 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 91
Study 3492974 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 91
Study 2639785 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dibasic sodium citrate in poloxamer 407 (test dentifrice)
Number of subjects: 175
Study 2639785 — intervention group
Group type: COMPARATOR
Intervention: 0.76% sodium monofluorophosphate (control dentifrice)
Number of subjects: 175
Study 31755634 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and treatment for HCV
Number of subjects: 12246
Study 31755634 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening programs
Number of subjects: 12246
Study 31755634 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of serological status
Number of subjects: 12246
Study 31301054 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQun® (ophthalmic solution of Coenzyme Q10 and Vitamin E)
Number of subjects: 612
Study 31301054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 612
Study 28489775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 7.5 μg/(kg × h) injected 30 minutes before anesthesia induction
Number of subjects: 60
Study 28489775 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60
Study 26003225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal direct current stimulation (rctDCS) with 2mA intensity and 20 min duration applied to the visual cortex, 5 consecutive sessions 1-5 days prior to menstruation.
Number of subjects: 20
Study 26003225 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (placebo control).
Number of subjects: 20
Study 26003225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal direct current stimulation (rctDCS).
Number of subjects: 20
Study 24002506 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Thermometer and Problem List (DT&PL)
Number of subjects: 220
Study 24002506 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 220
Study 21565138 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Kangliu Zengxiao Decoction (KLZX)
Number of subjects: 74
Study 21565138 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 74
Study 21565138 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with KLZX
Number of subjects: 74
Study 19223200 — intervention group
Group type: EXPERIMENTAL
Intervention: P-adiponectin
Number of subjects: 52
Study 19223200 — intervention group
Group type: EXPERIMENTAL
Intervention: P-leptin
Number of subjects: 52
Study 19223200 — intervention group
Group type: EXPERIMENTAL
Intervention: U-adiponectin
Number of subjects: 52
Study 19223200 — intervention group
Group type: EXPERIMENTAL
Intervention: U-leptin
Number of subjects: 52
Study 19223200 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 52
Study 19223200 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR
Number of subjects: 52
Study 16980837 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy conservation intervention
Number of subjects: 0
Study 16980837 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study 15117407 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT after downregulation
Number of subjects: 0
Study 15117407 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT in menopause
Number of subjects: 0
Study 15117407 — intervention group
Group type: EXPERIMENTAL
Intervention: HST in the natural cycle
Number of subjects: 0
Study 15117407 — intervention group
Group type: EXPERIMENTAL
Intervention: Down regulation plus HRT
Number of subjects: 0
Study 15117407 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural cycle plus HRT
Number of subjects: 0
Study 15117407 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopause plus HRT
Number of subjects: 0
Study 15117407 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural cycle
Number of subjects: 0
Study 11014951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular progesterone (200 mg/day)
Number of subjects: 96
Study 11014951 — intervention group
Group type: COMPARATOR
Intervention: Intravenous albumin (100 ml of 20%)
Number of subjects: 96
Study 9241103 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 1 g day(‐1) for 4 weeks
Number of subjects: 20
Study 9241103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 20
Study 8355939 — intervention group
Group type: EXPERIMENTAL
Intervention: Polybutester skin suture
Number of subjects: 50
Study 8355939 — intervention group
Group type: COMPARATOR
Intervention: Nylon skin suture
Number of subjects: 50
Study 8355939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both suture materials
Number of subjects: 50
Study 3721630 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐adrenergic blockade
Number of subjects: 12
Study 3721630 — intervention group
Group type: COMPARATOR
Intervention: Control (no beta-blockade)
Number of subjects: 12
Study 30352317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to increase physical activity and improve diet
Number of subjects: 953
Study 30352317 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline response efficacy
Number of subjects: 953
Study 26987489 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician Judgment
Number of subjects: 111
Study 26987489 — intervention group
Group type: EXPERIMENTAL
Intervention: Death or Disability Estimates
Number of subjects: 111
Study 24956496 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (telaprevir, ribavirin, pegylated-interferon alfa)
Number of subjects: 136
Study 24956496 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (boceprevir, ribavirin, pegylated-interferon alfa)
Number of subjects: 136
Study 22079391 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (Q10) supplementation at a dose of 90 mg daily for 8 weeks
Number of subjects: 23
Study 22079391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 22079391 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (Q10) supplementation
Number of subjects: 23
Study 19517167 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 220
Study 19517167 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 220
Study 18386567 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb combined with enteral nutrition (10% rhubarb liquid medication, 100 mL before operation, 50 mL at 18th and 42th hour post-operation)
Number of subjects: 56
Study 18386567 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition via nasal feeding (starting from the 42nd hour to the 8th day after operation)
Number of subjects: 56
Study 18386567 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid supplement and parenteral nutrition
Number of subjects: 56
Study 15723737 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pancreatitis (AP) patients
Number of subjects: 52
Study 15723737 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer (CA) patients
Number of subjects: 52
Study 15723737 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study 12537464 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate beer consumption (330 mL of beer/day for 30 days)
Number of subjects: 48
Study 12537464 — intervention group
Group type: COMPARATOR
Intervention: Mineral water (control group)
Number of subjects: 48
Study 11022808 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 176
Study 11022808 — intervention group
Group type: COMPARATOR
Intervention: No alcohol consumption
Number of subjects: 176
Study 9068514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic Balloon Pump (IABP) for 48 hours
Number of subjects: 102
Study 9068514 — intervention group
Group type: COMPARATOR
Intervention: Control (no IABP)
Number of subjects: 102
Study 9068514 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with recurrent ischemia
Number of subjects: 102
Study 9068514 — intervention group
Group type: COMPARATOR
Intervention: Control (no recurrent ischemia)
Number of subjects: 102
Study 9068514 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with adverse clinical events (death, stroke, reinfarction, emergency revascularization)
Number of subjects: 102
Study 9068514 — intervention group
Group type: COMPARATOR
Intervention: Control (no adverse clinical events)
Number of subjects: 102
Study 8340155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridogrel (300 mg)
Number of subjects: 16
Study 8340155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3032537 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar administration (5-g minitablets, three times per day with main meals for 8 weeks)
Number of subjects: 29
Study 3032537 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar administration
Number of subjects: 29
Study 3032537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31522924 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (app) for reporting symptoms, used weekly or sooner if symptoms worsened
Number of subjects: 60
Study 31522924 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (app) for reporting symptoms
Number of subjects: 60
Study 31522924 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 60
Study 31337168 — intervention group
Group type: EXPERIMENTAL
Intervention: Interfascial injection (IF Group)
Number of subjects: 56
Study 31337168 — intervention group
Group type: COMPARATOR
Intervention: Perivascular injection with nerve stimulation (PV Group)
Number of subjects: 56
Study 31337168 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IF Group and PV Group
Number of subjects: 56
Study 28033130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Number of subjects: 84
Study 28033130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 27337795 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS delivered to the left dorsolateral prefrontal cortex, 2 times daily for 10 days
Number of subjects: 70
Study 27337795 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 70
Study 27337795 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 70
Study 23819344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose perindopril and amlodipine combination
Number of subjects: 82
Study 21976185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi‐Ox80 mask
Number of subjects: 6
Study 21976185 — intervention group
Group type: COMPARATOR
Intervention: Heliox21 mask
Number of subjects: 6
Study 21976185 — intervention group
Group type: COMPARATOR
Intervention: Standard high-concentration face mask
Number of subjects: 6
Study 18379751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track treatment
Number of subjects: 50
Study 18379751 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 50
Study 16564862 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 F sphincterotome
Number of subjects: 107
Study 16564862 — intervention group
Group type: COMPARATOR
Intervention: 5 F sphincterotome
Number of subjects: 107
Study 12672842 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-pin external fixator
Number of subjects: 50
Study 12672842 — intervention group
Group type: COMPARATOR
Intervention: Four-pin external fixator
Number of subjects: 50
Study 10765092 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy combined with adjuvant mitomycin C (MMC; 15 mg/m(2) i.v. q 6 weeks)
Number of subjects: 189
Study 10765092 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy alone (ORCH)
Number of subjects: 189
Study 8889684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0, 0.28, 0.52 g/kg)
Number of subjects: 18
Study 8889684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (4, 48, 96 mg/70 kg)
Number of subjects: 18
Study 8889684 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (0, 1.75, 3.55% THC)
Number of subjects: 18
Study 8889684 — intervention group
Group type: COMPARATOR
Intervention: Drug Recognition Examiner (DRE) assessments
Number of subjects: 18
Study 1893348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural doxorubicin plus LC9018 (38 patients)
Number of subjects: 76
Study 1893348 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone (38 patients)
Number of subjects: 76
Study 1893348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural doxorubicin plus LC9018
Number of subjects: 76
Study 6550147 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype health education curriculum
Number of subjects: 60
Study 6550147 — intervention group
Group type: COMPARATOR
Intervention: Traditional health screening program
Number of subjects: 60
Study 31050707 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab (200 mg every 3 weeks)
Number of subjects: 542
Study 31050707 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy (paclitaxel 175 mg/m2, docetaxel 75 mg/m2, or vinflunine 320 mg/m2, all every 3 weeks)
Number of subjects: 542
Study 31050707 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 542
Study 29139592 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g single dose systemic acetaminophen
Number of subjects: 70
Study 29139592 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 70
Study 29139592 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral opioid consumption
Number of subjects: 70
Study 25596179 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF, 300 mg/day) monotherapy
Number of subjects: 90
Study 25596179 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF, 300 mg/day) and entecavir (ETV, 1 mg/day) combination therapy
Number of subjects: 90
Study 24449105 — intervention group
Group type: EXPERIMENTAL
Intervention: Centre-based exercise group (n = 10)
Number of subjects: 27
Study 24449105 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise group (n = 8)
Number of subjects: 27
Study 24449105 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 27
Study 22039171 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) delivered orally (50 mg)
Number of subjects: 18
Study 22039171 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) delivered to proximal small bowel (PSB) (50 mg)
Number of subjects: 18
Study 22039171 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) delivered to distal small bowel (DSB) (50 mg)
Number of subjects: 18
Study 22039171 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) delivered to ascending colon (AC) (50 mg)
Number of subjects: 18
Study 22039171 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs)
Number of subjects: 18
Study 18997106 — intervention group
Group type: EXPERIMENTAL
Intervention: Agaricus sylvaticus (30 mg/kg/day)
Number of subjects: 56
Study 18997106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 17447668 — intervention group
Group type: EXPERIMENTAL
Intervention: High-to-low workload condition
Number of subjects: 198
Study 17447668 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-high workload condition
Number of subjects: 198
Study 15043687 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin for 1 week
Number of subjects: 11
Study 15043687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 12148426 — intervention group
Group type: EXPERIMENTAL
Intervention: Zipper device for skin closure
Number of subjects: 610
Study 12148426 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 610
Study 9497182 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbohydrate solution (CHO; 170 +/- 6 g glucose)
Number of subjects: 7
Study 9497182 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbohydrate electrolyte with 5% MCT solution (CHO + MCT; 85 +/- 3 g MCT)
Number of subjects: 7
Study 9497182 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% MCT solution
Number of subjects: 7
Study 9497182 — intervention group
Group type: COMPARATOR
Intervention: artificially colored and flavored water (placebo)
Number of subjects: 7
Study 8803911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy including hydroxychloroquine, methotrexate, and sulphasalazine
Number of subjects: 0
Study 8803911 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 0
Study 2317424 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 8% glucose
Number of subjects: 30
Study 2317424 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 0.83% glucose
Number of subjects: 30
Study 2317424 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 0.33% glucose
Number of subjects: 30
Study 2317424 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with any glucose concentration
Number of subjects: 30
Study 6988172 — intervention group
Group type: EXPERIMENTAL
Intervention: Feprazone (800 mg daily for 2 days, then 600 mg daily for up to 8 days)
Number of subjects: 24
Study 6988172 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone (800 mg daily for 2 days, then 600 mg daily for up to 8 days)
Number of subjects: 24
Study 30630753 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation-Based Balance Training (PBT)
Number of subjects: 16
Study 30630753 — intervention group
Group type: COMPARATOR
Intervention: Traditional Balance Training (Control)
Number of subjects: 16
Study 28698320 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE for COPD(C) self‐management programme delivered over 5 months (six sessions, group-based)
Number of subjects: 0
Study 28698320 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25780062 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 11
Study 25780062 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus chemotherapy (cyclophosphamide)
Number of subjects: 11
Study 25780062 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 11
Study 24552972 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual body swapping with mental rehearsal (VBS)
Number of subjects: 39
Study 24552972 — intervention group
Group type: COMPARATOR
Intervention: Watching movement only
Number of subjects: 39
Study 24552972 — intervention group
Group type: COMPARATOR
Intervention: Mental rehearsal only
Number of subjects: 39
Study 23304686 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-activated disinfection (LAD) (FotoSan)
Number of subjects: 80
Study 23304686 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LAD)
Number of subjects: 80
Study 19892713 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 26
Study 19892713 — intervention group
Group type: COMPARATOR
Intervention: QuickOpt
Number of subjects: 26
Study 17341565 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (40 mg every second day)
Number of subjects: 63
Study 17341565 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg daily)
Number of subjects: 63
Study 17341565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of testosterone and estradiol
Number of subjects: 63
Study 17341565 — intervention group
Group type: COMPARATOR
Intervention: Control (Testosterone alone)
Number of subjects: 63
Study 15761754 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration of enalaprilat (>50 ng/ml)
Number of subjects: 40
Study 15761754 — intervention group
Group type: COMPARATOR
Intervention: Low concentration of enalaprilat (<10 ng/ml)
Number of subjects: 40